ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alembic Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Declaration Of Voting Results Of The Postal Ballot
Pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and above referred Postal Ballot Notice, we would like to inform you that the following special resolution have been passed by the members of the Company with requisite majority: 1. Appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company. The aforesaid resolution is deemed to have been passed effectively on the last date specified for remote e-voting i.e. 17th March, 2022. Please find enclosed herewith the Voting Results of Postal Ballot along with Scrutinizer's Report in this regard. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Macitentan Tablets, 10 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
Alembic Pharmaceuticals joint venture gets USFDA nod for anti-fungal drug
Alembic Pharmaceuticals Ltd on Tuesday said its joint venture, Aleor Dermaceuticals Ltd (Aleor), has received final approval from the US health regulator for its generic version of Nystatin and Triamcinolone Acetonide ointment used for the treatment of cutaneous candidiasis. Cutaneous candidiasis is an infection of the skin and nails caused by the candida fungus. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment of strength 100,000 units/gram, Alembic Pharmaceuticals said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Nystatin and Triamcinolone Acetonide ointment of Taro Pharmaceuticals USA Inc, it added. The company further said Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis. It has been demonstrated that the nystatin-steroid combination provides... ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). The details are provided in the attached letter. We enclose herewith an e-mail intimation(s) received from Link lntime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). The details are provided in enclosed letter. We enclose herewith an e-mail intimation(s) received from Link lntime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to our intimation dated 28th January, 2022 regarding schedule of Post Results Conference Call, please find enclosed herewith the transcript of the said Conference Call held on 10th February, 2022. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, we enclose herewith a copy of notice published in English and vernacular language (Gujarati) newspaper on 16th February, 2022 in Economic Times English Edition and Financial Express Gujarati Edition informing the members inter alia about the completion of dispatch of Notice of Postal Ballot dated 10th February, 2022 and E-voting information, in respect of the Special Resolution for appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). The details are provided in the attached letter. We enclose herewith an e-mail intimation(s) received from Link lntime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.